Home

Galapagos NV - American Depositary Shares (GLPG)

22.71
+0.02 (0.09%)

Galapagos NV is a biotechnology company focused on the discovery and development of innovative treatments for a variety of diseases, particularly those affecting the immune system and the central nervous system

The company leverages its proprietary target discovery platform and extensive drug development expertise to create therapeutics that aim to address significant unmet medical needs. With a commitment to advancing science through collaboration and research, Galapagos-NV works towards bringing novel therapies from laboratory to clinic, ultimately striving to improve patient outcomes and quality of life.

SummaryNewsPress ReleasesChartHistoricalFAQ
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...
Via Newsfile · May 30, 2024
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers
By Frontier Medicines · Via GlobeNewswire · February 22, 2024